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ABSTRACT
Objectives: Patients and policy makers advocate that
drug treatments should be individualised. However, the
term is used in a variety of ways. We set out to identify
the range of related terminology and concepts in the
general field of individualisation, map out the
relationships between these concepts and explore how
patients’ perspectives are considered.
Design: We consulted members of an established patient
and public involvement group about their experience of
medicine taking for long-term conditions and their ideas
about individualisation. We then conducted a scoping
review of the literature to explore how terms surrounding
individualisation of drug treatment are used and defined in
the literature, and to explore the extent to which patients’
perspectives are represented, with a view to informing
future recommendations as to how individualisation can be
operationalised.
Methods:We identified relevant literature using a range of
search strategies. Two researchers independently extracted
definitions of terms using a template. Inductive and
deductive methods were used to explore the data.
Results: Definitions were categorised according to the
following themes: medical management;
pharmacogenetics, the patient’s perspective; interactions
between the healthcare provider and patient and
management of long-term conditions.
Conclusions:Within the literature reviewed, the
involvement of patients in the ongoing management of
drug treatment was largely absent. We propose the use of
a new term ‘mutually agreed tailoring’ (MAT). This
describes the ongoing pharmacological management of
conditions that incorporates patients’ specific needs,
experiences and existing strategies for using their
medications, and the professionals’ clinical judgement.
This usually includes patients monitoring their symptoms
and, with the support of the professional, making
appropriate product, dose or timing adjustments as
necessary. Our previous work suggests that many patients
and doctors are successfully practising MAT, so we
suggest that a formal description may facilitate wider
utilisation of strategies that will improve patient outcomes.
INTRODUCTION
Patients with long-term conditions often
need to take several drugs to help manage
their illness. They are required to manage
these medications on a daily basis, and thus
need to be involved in their treatment.
Patients and policy makers1 advocate that
treatments are individualised, and ‘shared
decision-making’ is advocated,2 although the
terms individualisation and shared decision-
making are used in a variety of different
ways.
From a recent interview study with doctors
we found that, while individualisation was
considered to be beneﬁcial, understandings
of what it meant were variable.3 Methods
used to achieve individualised treatment are
frequently discussed in relation to making
drug treatment decisions (ie, whether the
patient should use a speciﬁc drug or not).
Few doctors discuss the use of strategies to
support patients to individualise their own
treatments after the consultation by, for
example, making sure that the dose and
timing of any drug is appropriate for the
individual patient.3 We set out to explore this
concept further, and to identify how the
term is used in the literature.
If clinically relevant research is going to
help patients manage long-term conditions,
then it needs to address their concerns. It is
widely acknowledged that research should
address issues that are of relevance to
patients4; however, much research is
Strengths and limitations of this study
▪ By conducting workshops with a patient and
public involvement group and a scoping review,
we identified dissonance between lay and profes-
sional notions of individualisation.
▪ Strategies such as the use of a data extraction
template and multiple coders were used to min-
imise risks of bias being introduced into the
review.
▪ We aimed to identify a typology of papers which
discussed individualisation, rather than a com-
prehensive list. It is possible that relevant articles
were missed.
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conducted without consulting them.4 To try and ensure
the relevance of the work reported here to patients, we
sought the advice of an established patient and public
involvement (PPI) group, which has experience of con-
tributing to all stages of research including question gen-
eration.5 We asked them what individualisation of drug
therapy meant to them, in the context of their own long-
term conditions. The group’s main points and recom-
mendations are summarised below.
‘Individualisation’ was seen by our PPI group as a way
of potentially minimising the negative impact of burden-
some medication regimes.6 It occurs when patients are
involved in the initial decisions and the ongoing
pharmacological management of their conditions.
Accordingly, initial treatment decisions should be nego-
tiated between the patient and the general practitioner
(GP) after consideration of patients’ individual needs,
lifestyles, and coexisting conditions and medications. If
requested, patients should be given information about
the purpose, harms and beneﬁts of particular treat-
ments; however, patients may also research this for them-
selves. With the support of healthcare providers, patients
should also be involved in the ongoing monitoring and
adjustment of doses. Members of the group described
situations in which they had increased or decreased the
dosage of particular treatments until it suited their indi-
vidual needs, corroborating previous research.7 The role
of the doctor should be to set safe parameters within
which patients can adjust their medications, to inform
patients what to expect when taking a new drug and to
highlight potential side effects that would require imme-
diate action (eg, which side effects should lead to the
immediate discontinuation of the treatment and which
should be tolerated if possible). The group recognised
limitations to this description of individualisation. It was
noted that not all patients want their treatments to be
individualised in this way. Second, patients described the
considerable level of involvement required of the
patient. It was acknowledged that not all patients will be
motivated to make such an effort. Third, with this
approach comes the potential for patients to be left
feeling unsupported. Finally, the group recognised that
individualisation of treatment is challenging (if not
impossible) without continuity of care.
We (the authors of this paper) met to discuss these
views in the light of our previous ﬁnding that the terms
used to describe such activities were varied and confus-
ing, although some doctors appeared to be doing what
our PPI group recommends.3 We thought that a new
term might help deﬁne the need and activities identi-
ﬁed—that is, ‘mutually agreed tailoring’ (MAT). The
aim of this paper is to explore how other terms sur-
rounding individualisation are used in the published lit-
erature, and whether or not they address the issues
raised by the PPI group.
OBJECTIVES
To conduct a scoping review of the literature to (1) iden-
tify the range of related terminology and concepts in
the general ﬁeld of individualisation of drug treatment,
(2) map out the relationships between all these concepts
and (3) to assess the extent to which the ideas presented
in the literature reﬂect the needs identiﬁed by our PPI
group.
METHODS
A broad scoping exercise was conducted with the objec-
tives of providing a preliminary map of the literature
(eg, numbers and types of papers); to assist in deﬁning
parameters for a full review (eg, populations, medical
specialties, methodologies, outcomes) and to assess the
feasibility of conducting a systematic review.8
Preliminary search terms were developed by the
research team to reﬂect the core concepts identiﬁed
from our previous qualitative study with physicians, and
our discussions with the PPI group, about the methods
used to individualise treatments.3 This included the
terms tailored, drug monitoring, personalised and dose
adjustment, and a protocol for the review was produced.
Database searches were conducted in 2012 (in
MEDLINE, MEDLINE in Process, EMBASE, CENTRAL,
Conference Proceedings Citation Index—Science, and
Social Science and Humanities) using the various terms
for individualisation (table 1). The strategies produced
in excess of 100 000 hits. Papers identiﬁed by these
searches were collated and three randomly sampled
batches of 100 abstracts were independently screened by
two of the researchers, and consensus was achieved
through discussion with the wider team.
The purpose of screening was to identify a typology of
papers which discuss individualisation.
Abstracts were excluded if they were not speciﬁcally
about individualisation (eg, were about shared decision-
making in its broadest sense or about personalised care
budgets). This produced 22 included papers that were
charted to demonstrate the breadth and depth of the lit-
erature.8 As the purpose of the review was to identify
Table 1 Extract of search terms from the scoping search
1 (‘n of 1’ adj3(trial* or stud*)).tw.
2 ((individuali* or personali* or tailor*) adj3(medic* or
treat* or care or healthcare or therap* or manag* or
regimen* or drug?)).tw.
3 individualised medicine/
4 ((‘single participa*’ or ‘single patient*’ or ‘single case*’
or ‘single subject*’ or ‘individual participa*’ or ‘individual
patient*’ or ‘individual case*’ or ‘individual subject*’)
adj3(trial* or stud* or design*)).tw.
5 ‘self monitor*’.tw.
6 (monitor* adj2(their or own or themselves)).tw.
7 ((individually or personally) adj1 tailored).tw.
8 ((patient or person or client) adj1(cent?red or focus?ed
or oriented or led)).tw.
9 patient centered care/
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concepts, it was not necessary to conduct quality
appraisal.
The scoping review revealed the complexity of the lit-
erature. Many papers about individualisation are com-
mentaries or opinion pieces, written from a particular
author’s perspective, or contribute to a discourse or
ideology and were important to capture. It was not pos-
sible to identify a keyword or set of keywords which pro-
duced a clearly delineated set of papers about
individualisation, which indicated a lack of conceptual
clarity or maturity of the literature which constrains the
possibility of conducting a systematic review of individu-
alisation of drug treatments, and no existing systematic
reviews of the topic were identiﬁed.
The scoping review identiﬁed 16 authors (table 2)
who had either contributed a key paper or presented a
particular perspective that warranted further explor-
ation.9 Author citations were searched, and authors were
contacted and asked if they could suggest any other
papers relevant to the literature search.10 Full texts were
retrieved for 68 articles for further screening which illu-
strated the diversity of interests (medical education, phil-
osophy and clinical practice) and perspectives
(humanism, cyber science and evidence-based policy).
A clear champion of individualisation was not identiﬁed.
Pooling the scoping and author reviews produced a
total of 90 papers for analysis.
Data extraction
The data were initially tabulated in a simple matrix,
which facilitated a preliminary exploration of the consti-
tuents, contexts and themes (table 3). Each of the
researchers read the deﬁnitions and contextual data and
identiﬁed the key constructs of individualisation, which
informed the data extraction template. Two researchers
independently extracted the deﬁnitions of individualisa-
tion, while the remaining team members extracted
deﬁnitions for 10% of the papers, and all researchers
reviewed and agreed upon the extracted data.
Data analysis
Deﬁnitions from the 90 papers were the units of analysis,
and the categories from the data extraction template
provided an analysis framework.11 Concurrent thematic
analysis facilitated a more nuanced exploration of the
data.12 The researchers categorised the deﬁnitions
according to the following themes: medical manage-
ment of conditions, pharmacogenetics, the patients’ per-
spective, interactions between healthcare providers and
patients and long-term management of conditions.
RESULTS
Terms pertaining to individualisation in its broadest
sense are used inconsistently to refer to a multitude of
factors. The terms personalised and individualised are
often used interchangeably, and there appears to be no
evidence that either term is used to refer to particular
qualities more than the other. Many papers present deﬁ-
nitions that are vague—it is common to ﬁnd deﬁnitions
such as “Personalisation simply means the right drug for
right patient at the right time”.13 Tautological deﬁnitions
are common, and a lack of context or reference can
undermine utility. Other deﬁnitions are polemical,
arguing that personalisation is needed without deﬁning
the concept or clarifying how it is achieved.
As personalisation and individualisation are often used
interchangeably we will use the term individualisation.
Medical management
Some deﬁnitions of individualisation focus exclusively
on the medical management of conditions. Treatments
are considered to be individualised if patients are
divided into subgroups (based on a range of factors), or
if comorbidities are considered. In this group of deﬁni-
tions, individualisation tends to be considered in rela-
tion to the prescribing of treatments rather than the
long-term management of the condition. The perspec-
tive of the patient is not considered. For some, evidence-
based medicine (EBM) and governance frameworks are
seen to be synonymous with individualisation, as the
healthcare provider has to identify the guideline or treat-
ment option that best suits the individual patient. In
contrast, others argue that EBM is the antithesis of indi-
vidualisation, stating that each patient is unique and
cannot be forced into standardised guidelines.
The following deﬁnition by the Academy of Medical
Science describes individualisation as a ‘medical model’.
This is an approach to healthcare in which the focus is
on the treatment of the underlying pathology of the
disease, negating factors such as the inﬂuence of the
environment and preferences of the patient:
[Personalisation is] a medical model in which medical
care is customised to individual patients14
Table 2 Author search and number of abstracts identified
Author
Number
of articles
retrieved Author
Number
of articles
retrieved
Jeffrey
Aronson
369 Gordan
Guyatt
1120
Cynthia Boyd 211 Cameron
Hay-Rollins
22
Alan Cribb 153 Rob Horne 88
Glynn Elwyn 243 Lez Irwig 293
Vicki Entwistle 124 Richard
Kravitz
237
Terri Fried 116 David Le
couteur
190
Paul Glasziou 441 Mary Tinetti 182
Francis
Griffiths
204
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Treatments are individualised to subgroups of the
population based on different factors that inﬂuence sus-
ceptibility to a certain condition. Deﬁnitions vary with
regard to the factor(s) used to deﬁne subgroups; they
may include genetics, age, family history or gender. The
focus is on maximising the therapeutic effectiveness,
rather than incorporating the patient’s preferences and
lifestyles. Treatments are designed to reduce the risk
associated with drug treatment, to maximise the beneﬁts
and minimise the harms from the perspective of the
prescriber:
Personalized Medicine refers to the tailoring of medical
treatment to the individual characteristics of each
patient…to classify individuals into subpopulations that
differ in their susceptibility to a particular disease or
their response to a speciﬁc treatment. Preventative or
therapeutic interventions can then be concentrated on
those who will beneﬁt, sparing expense and side-effects
for those who will not15
For some, this is achieved through EBM and the skill
of the practitioner. Rather than categorising patients at
the cellular level (as is the case with pharmacogenetics),
EBM focuses on the categorisation of patients based on
age, gender and family history. The healthcare provider
plays a signiﬁcant role in eliciting and balancing mul-
tiple factors to effectively diagnose and treat the patient.
However, the perspective of the patient is still absent:
From the time of Hippocrates and to the present day all
medical students are diligently taught to elicit individual
patients’ family history, past medical history and corrob-
orate this with clinical symptoms and signs…Thus essen-
tially EBM is truly the ‘personalised medicine.’ It is the
acceptable form of ‘good medical practice’16
Pharmacogenetics
Among the literature that we reviewed, the development
of pharmacogenetics was dominant and frequently con-
sidered to be the ultimate form of individualisation. This
allows for the identiﬁcation of subgroups of patients
likely to respond to treatment based on variations in
genetics:
Using high throughput array technologies, it is possible
to analyse thousands of genes or gene products simultan-
eously, resulting in an individual gene or gene expression
proﬁle (signature). These data increasingly allow to
deﬁne the individual risk for a given disease and to
predict the individual prognosis of a disease as well as
the efﬁcacy of therapeutic strategies (individualized
medicine)17
In contrast to the quote above in which EBM is consid-
ered to be truly personalised medicine, the quote below
describes EBM as counter to individualised medicine. This
is due to the perception that the prioritisation of science
undermines the ‘personal’ element that was essential in
traditional medical practice. Pharmacogenetics is seen as
the solution to repersonalising medicine on a scientiﬁc
basis by combining the personal (but largely non-
scientiﬁc) methods of old with evidence-based (but not
personal) methods:
Table 3 Extract from data matrix
Author(date) Definition Terms used
Constituents of
definition
Researcher
theme
Bates (2010) “Personalized medicine refers to the tailoring of
medical treatment to the individual
characteristics of each patient. It does not
literally mean the creation of drugs or medical
devices that are unique to a patient but rather
the ability to classify individuals into
subpopulations that differ in their susceptibility
to a particular disease or their response to a
specific treatment. Preventive or therapeutic
interventions can then be concentrated on those
who will benefit, sparing expense and side
effects for those who will not”
Personalised Subgroups
Preventative
medicine
Minimising side
effects
Medical
management
Luijks (2012) “GPs agreed on the need to adapt management
of multimorbidity to personal circumstances of
these patients, such as vitality, personal
preferences (for example retaining
independence as the ultimate goal) and
socioeconomic conditions. They stressed the
importance of tailoring care to the individual and
tried to understand the meaning of illness for a
person”
Individualised Multimorbidity
management
Personal
circumstances
Patient preferences
Meaning of illness
for the individual
Consideration of
patient factors
GPs, general practitioners.
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Personal medicine was lost with the advent of scientiﬁc,
evidence-based medicine. This loss is deplored by many
patients and is one of the reasons for the attractiveness of
alternative medicine. Now, medicine needs to be
re-personalized on a scientiﬁc basis18
However, as we discuss below, some writers describe
pharmacogenetics and EBM as reductionist and suggest
that they depersonalise medicine.
The concept of ‘preventative healthcare’ features in a
number of articles about pharmacogenetics. This refers
to screening and other procedures that are undertaken
to predict and prevent (or delay) a disease before it
occurs. As preventative procedures occur before the
onset of the condition, the patient has to be proactive in
requesting the necessary course of action. In the follow-
ing deﬁnition, Pfaff et al19 equate personalised medicine
with proactive and preventative medicine:
Personalized medicine enables patients to be more pro-
active. Proactive managed care means screening, early
treatment, prevention, the use of information technology,
electronic medical records and decision-making tools
Similarly, the deﬁnition provided by the European
Science Foundation (ESF) also refers to proactive, pre-
emptive and preventative healthcare:
In essence, personalised medicine represents a shift from
reactive medicine to proactive, pre-emptive and prevent-
ive healthcare20
In that report, the authors go on to describe ‘proactive
P4 medicine’ which refers to healthcare that is predict-
ive, preventive, personalised and participatory.19 A dis-
cussion of the differences between the terms proactive,
pre-emptive and preventative is beyond the scope of this
paper; however, all refer to actions taken by the patient
or the healthcare provider to predict and prevent the
onset of a disease. Participatory in the sense used by ESF
has a similar meaning to the term ‘responsibilisation’
(see below) as suggested by the Nufﬁeld Council on
Bioethics.21
While some authors criticise pharmacogenetics for
ignoring the impact of the natural and social environ-
ment, lifestyle features strongly in some of the longer,
more comprehensive deﬁnitions of pharmacogenetics
such as that provided in the report by the ESF:
Personalised medicine…seeks to integrate data on the
entire dynamic biological makeup of each individual as
well as the environmental and lifestyle factors that inter-
face with this makeup to generate a complex, individual
phenotype20
The narrow focus on pharmacogenetics, and the view
that this alone will lead to ultimate individualised treat-
ment is considered by some to be unwarranted and
counterproductive:
We still lack even a basic framework that permits the mul-
tiple patient attributes that inﬂuence the effect of treat-
ment -. ‘pharmacogenomic exceptionalism’—the notion
that genetic information is uniquely important in deter-
mining the risks and beneﬁts of treatments—is clearly
unwarranted and counterproductive to the broadly
shared goal of tailoring care to individuals22
While recognising the importance of the environment
and the dangers of a narrow focus on pharmacogenet-
ics, these two deﬁnitions focus on the inﬂuences of the
natural environment on the patient’s responses to treat-
ment. This is considerably different to the deﬁnition
proposed by Burgener et al23 in which the patient’s
social environment is emphasised, although it is unclear
how this should inform treatment decisions:
[treatment should be] based on the patient’s disease,
physical and psychological needs, family history, life
events, habits, friends, hobbies etc. Special emphasis
should be put on the patient’s own needs and prefer-
ences. The focus on individuality includes past environ-
mental and cultural inﬂuences that affect the person’s
response pattern.
The patient’s perspective
Pharmacogenetics and online genetic tests are not ‘per-
sonalized’ but stratiﬁed, information is less a ﬁrm predic-
tion and more an estimation of risk, and increased
‘choice’ can be anxiety provoking, confusing and leave
an individual feeling abandoned and uncared for.24
Some writers are critical of the idea that medically
focused treatment, such as pharmacogenetics, and EBM
have anything to do with individualisation. They argue
that individualisation requires patients’ perspectives,
values, preferences and experiences to be considered.
This would require patients to be actively involved in
their care, and healthcare providers treating the whole
person—not just their disease. However, aspects of deﬁ-
nitions that focus on the preferences of patients tend to
focus on social or lifestyle choices, and not the manage-
ment of drugs. These articles are frequently polemical
and do not explain how individualisation could be
achieved.
The following quote is taken from a qualitative study
of GPs. This particular quote is presented in that paper
under the heading of ‘individualisation’.25 It describes
how GPs see individualisation as the inclusion of a range
of factors such as the patients’ preferences in treatment
decisions. However, the authors do not contextualise
this, and it is not clear if patients’ values have to be spe-
ciﬁc to their health or if a broader range of values are
considered. While emphasising the importance of tailor-
ing care to the individual, the authors do not provide
any suggestions as to how to elicit the meaning of the
illness for the person, or how this might inform treat-
ment decisions:
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GPs agreed on the need to adapt management of multi-
morbidity to personal circumstances of these patients,
such as vitality, personal preferences (for example retain-
ing independence as the ultimate goal) and socio-
economic conditions. They stressed the importance of
tailoring care to the individual and tried to understand
the meaning of illness for a person25
As discussed above, authors take different views as to
whether EBM or pharmacogenetics is the ultimate form
of individualised treatment. However, for others pharma-
cogenetics and EBM depersonalise medicine; they
suggest that patient involvement is the only way to really
personalise treatment:
As our medical decisions become more and more stan-
dardized and codiﬁed, we should take care to ensure that
critical therapeutic choices are not based exclusively on
formal guidelines. Many decisions need to be individua-
lized, especially when they involve choices between pos-
sible outcomes that may be viewed differently by different
patients26
This is not to say that patients’ preferences are not
considered in EBM. Some authors writing from an EBM
perspective argue that EBM does incorporate the views
of the patient. This usually refers to the extent to which
patients want to be involved in treatment decisions, or if
the patient has a preference for a speciﬁc treatment
over another. How the patient uses the treatment on a
day to day basis is rarely considered.
EBM is individual patient oriented and clearly recognises
individual needs. The process of individualised EBM
decision making uses guides to address the credibility of
subgroup analyses, approaches to incorporating individ-
ual patient values and preferences, and individualized
RCTs (N-of-1 RCTs)27
The science versus art discourse is a strong theme in
the literature. While in the quote above, EBM is seen as
individualised, other authors consider approaches such
as ‘the art of medicine’ to be the only approach capable
of individualising treatment. This is an approach to
medical practice that emphasises the need to treat the
patient with empathy and compassion. There is a tem-
poral perspective to this argument which reﬂects
changes in medical practices. Tutton28 describes how
the development of laboratory sciences was contested by
physicians of the time, who feared that its progression
would eradicate patient individuality. Despite the shared
use of the term personalised, the two meanings of the
term are conﬂicting:
During the latter part of the 19th century, as laboratory
sciences mobilized support from various quarters around
their promise to revolutionize medicine, physicians con-
tested this future. They stressed the ‘art’ of medical prac-
tice, which was founded upon a privileged epistemology
of patient individuality in contradistinction to the
universalization of knowledge represented by the labora-
tory sciences. This rhetoric conjured up an image of an
individualized medicine that was part and parcel of elite
physicians’ professional identity during that period in
Britain28
Generally, the literature is vague in the way in which
individualisation is described in relation to eliciting the
patient’s perspective. While it is often stated that the
patients’ needs and wants have to be considered, these
are typically neither qualiﬁed nor quantiﬁed in relation
to either healthcare or other aspects of their lives. In a
report undertaken by the National Health Service
(NHS) National Prescribing Centre entitled ‘Moving
towards Personalised Medicines Management’ Picton29
suggests that medicines are:
personalised to the needs and wants of each individual,
especially the most vulnerable and those in greatest
need, providing access to services at the time and place
of their choice
Without clarifying what personalisation is, the report
suggests various examples of ways in which it can be
achieved in clinical practice. One example is the use of
medication use reviews (MURs) during which healthcare
providers review the patient’s medicines in order to
maximise the effectiveness of the treatment plan and
identify any unnecessary medications. The extent to
which MURs incorporate the ‘needs and wants’ of each
individual is unclear. It is also hard to see the ‘individua-
lised element’ in some of their other suggestions for
achieving individualised treatment.
In a report written for the Nufﬁeld Council on
Bioethics, a number of uses of the term personalised are
discussed. The authors of the report are cautious about
the use of the term for a number of reasons; one being
that “the term personalisation, despite, or perhaps
because of its obvious rhetorical appeal and widespread
use in several ﬁelds of policy, is ambiguous and has
many different meanings and implications”.21 The
report provides four uses of personalisation and
acknowledges that each use of the term could potentially
conﬂict with another (as is the case in the following two
deﬁnitions). In the two uses of the term presented
below, patient involvement is dominant. Personalisation
is seen as being holistic care, incorporating patients’ pre-
ferences and lifestyles. No recommendations are pro-
vided for how this may be achieved. In the ﬁrst sense,
personalisation is:
Management or treatment that is personalised in the
sense of treating each individual as a ‘whole person’ and
being respectful of their particular wishes, worldview, life-
style, and health status overall for example (which might
of course include wishes not to take responsibility for
managing their own care).21
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In the second sense, personalisation is seen to be the
act of encouraging the patients to be active managers of
their care (to avoid misunderstanding, the authors of
the report chose to use the term ‘responsibilisation’
instead of personalisation when discussing this issue).
However, this refers more to the ability of the patients to
manage healthcare appointments and take medication
as prescribed than their involvement in drug treatment
decisions:
Medical care that is personalised in the sense that more
responsibility for management of healthcare is primarily
laid on or taken by individuals or their carers rather than
on medical professionals21
The other two uses of the term presented in the
report focus less on the patient and refer to technolo-
gies (such as pharmacogenetics) or to patients as consu-
mers of healthcare.
In the group of deﬁnitions in which the patients’ per-
spectives are considered, authors generally refer to indi-
vidualised care or healthcare. For these authors,
individualised care is not speciﬁc to drug treatment (in
some cases, not about drug treatment at all). For
example, in the nursing literature, individualised care
results when the nurse:
Knows the patient as a unique individual, and tailors
nursing care to a patient’s experiences (including events
associated with illness, home, work and leisure); beha-
viours (including physical indicators and preferred
coping strategies); feelings; and perceptions (including
meanings ascribed to experiences and interpretations of
events)30
In a discussion paper, Cribb and Owens31 distinguish
personalised medicine from personalised healthcare;
the former focusing on medical (including drug) treat-
ment and the latter incorporating patients’ preferences.
Cribb and Owens argue that personalisation is an
‘orchestrating label’ under which involvement and part-
nership are subsumed. Personalisation is used in the lit-
erature to refer to a number of things (centring on
patient inclusion) that are considered to be important
in clinical practice. This has resulted in a situation in
which terms have lost all meaning and are simply vague.
Cribb and Owens differentiate between personalised
medicine (which takes into account the biological
characteristics of the patient being treated) and persona-
lised healthcare (which incorporates individual prefer-
ence). The authors suggest that policy documents often
promise to achieve personalisation (referring to both
elements), despite the two not always being
complementary.31
Interactions between healthcare providers and patients
Interactions between healthcare providers and patients
only feature in a small number of deﬁnitions and are
usually one aspect of a more complex deﬁnition. For
example, Moldrup32 refers to an “individualised indica-
tion arising through a dialogue between doctor and
patient” as being one element of individualisation.
Initiatives such as education, information sharing, com-
munication and relationship building are all mentioned as
promoting individualisation; however, such initiatives are
rarely speciﬁc to the management of drug treatments. In
the following deﬁnition, Hoffman discusses how treatment
becomes individualised by the doctors integrating many
different elements relevant to the management of condi-
tions. Shared decision-making is then used to identify
which goals the patient wishes to pursue:
Clearly, the concept of individualized medicine requires
a holistic and integrative approach…The doctor’s task
will be to condense all of these aspects into straightfor-
ward therapeutic options which can be discussed with
the patient. In a shared decision process, it will ultimately
be the patient’s choice as to what therapeutic goals will
be primarily pursued33
While consideration of interactions between health-
care providers and patients features strongly in papers
discussing concepts such as shared decision-making and
patient-centred care, which are not speciﬁcally about
drug treatment, this is absent from the majority of deﬁ-
nitions of individualisation that we reviewed.
Long-term management of conditions
Many of the deﬁnitions provided above focus on indi-
vidualisation as a one off prescribing decision, not as
part of a process. However, long-term conditions are
likely to change over time, and symptoms may improve
or worsen as patients respond to treatment or as the
condition progresses. Treatments need to be adapted to
reﬂect such developments. For some writers, this adapta-
tion of treatment in response to changes in the patient
has been termed individualisation:
The idea of ‘personalized medicine’ has seized the
imagination of many medical researchers. Instead of ‘one
pill cures all’, personalized medicine offers a strategy, a
list of treatment recommendations that depend on the
genetic makeup of the individual patient… But each indi-
vidual’s germ-line genome is ﬁxed over her lifetime,
while everything else changes, including her state of
health or illness, and response to treatments.34
Previous research has found that patients monitor
symptoms and modify medications accordingly. Terms to
describe this process include monitoring, dose adjust-
ment and self-management. Monitoring is deﬁned by
Glasziou et al35 as:
Periodic measurement that guides the management of a
chronic or recurrent condition. It can be done by clini-
cians, patients, or both
While monitoring itself is rarely referred to as individual-
isation, technological devices to support self-monitoring
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and dose titration are often considered to be promoting
individualised healthcare:
The technology of personalised health care is based prin-
cipally on the patient’s use of portable or implantable
systems that monitor a variety of physiological para-
meters, such as twenty-four-hour heart and respiratory
rate36
The focus is very much on the monitoring of physical
parameters, such as blood pressure, and not on the
patient’s experiences. It is likely that any adjustments
based on these measurements are exclusively made by
healthcare providers. In some cases, treatment targets
are ﬁxed, and the patient adjusts the dose or duration of
the treatment until the target is achieved.37 In other
cases, the treatment target is individualised to each
patient. For example, Strain38 identiﬁed individualised
glycated haemoglobin (HbA1c) targets for elderly
patients with diabetes based on patients’ age, frailty
status, comorbidities and baseline HbA1c values. Here,
patients are required to titrate their treatment doses to
achieve the desired level.
Although there is room for patients to be active in this
process, it is usually the healthcare provider who has the
ultimate control. However, others argue that the involve-
ment of the patient is crucial in the management of the
condition. In an editorial, Heisler39 suggests that:
Patients interpret, evaluate, and accept or reject doctors’
recommendations on the basis of their personal experi-
ence of their illness in the context of their lives; patients
often cooperate only with recommendations that coin-
cide with their own goals and ideas about their illness. By
actively participating, patients can communicate their
concerns, lifestyle, and priorities to the provider, enab-
ling their treatment regimen to be tailored to their indi-
vidual needs, values, and goals, thus maximizing the
likelihood of adherence.
This author then discusses an observational study in
which it was suggested that monitoring only leads to
improved outcomes if this is combined with a good com-
munication strategy between the patient and the health-
care provider.40
There are interventions in which patients are invited
to be involved in decisions about the goals and targets
for their pharmacological treatment. McManus et al41
described an intervention consisting of telemonitoring
and self-management in the control of hypertension
(the TASMINH2 trial). Patients in this trial were taught
to monitor their symptoms using a telemonitoring
device that transmitted results to the research team. A
trafﬁc light system indicated whether the reading was
above, below or on target. If a patient was above or
below target, they were asked to adjust treatment doses
in accordance with a preapproved titration schedule.41
Interventions of this kind may be considered to be
similar to N-of-1 trials, which are:
crossover studies performed within a single individual. A
typical n-of-1 trial will implement aspects of a group-level
crossover trial, but on an individual (patient) level. For
each patient, his/her individual treatment effect (ITE) is
estimated by the difference between the average
outcome observed during time periods (episodes) the
patient received treatment A and treatment B. Each
patient serves as his/her own control, and the ITE
obtained from the trial is directly applicable to the spe-
ciﬁc patient being treated42
N-of-1 trials are a methodology, and not an accepted
form of clinical practice. Having said this, there is anec-
dotal evidence that healthcare providers are using infor-
mal N-of-1 trials with patients to identify optimal
treatment. They are commonly referred to as individua-
lised medication effectiveness tests43 and involve a
process of trying a treatment or dose, monitoring, adjust-
ing as necessary and remonitoring until the ‘best’ dose
has been achieved. As with monitoring interventions,
N-of-1 trials may be completely controlled by healthcare
providers, with the patent having no input at all.
However, there is room in such tests for patients to have
considerable involvement in deciding treatment goals
and targets, and in monitoring dose adjustment.
DISCUSSION AND CONCLUSIONS
From sampling the broad body of literature, we con-
clude that terms surrounding individualisation are used
inconsistently and interchangeably to refer to a multi-
tude of concepts. There does not appear to be any evi-
dence that any one term is used to refer to speciﬁc
elements of individualisation more than any other. In
some cases, deﬁnitions of the same term are contradict-
ory. For example, some deﬁnitions focus exclusively on
managing the medical aspects of the patients’ condition,
without considering the long-term impact on the
patient. These deﬁnitions tend to centre on a technol-
ogy or governance issue, such as pharmacogenetics or
evidence-based guidelines. Most start from a clinical per-
spective and focus on a single consultation. Other
authors argue that such technologies actually deperson-
alise medical care and suggest that patients’ perspectives
must be considered. However, these articles are typically
polemical, with authors arguing that treatments should
be individualised, without clearly stating what this is, or
how it can be achieved. These ﬁndings suggest that
generic terms such as individualised should be avoided,
and that more speciﬁc terms, such as pharmacogenetics,
should be used whenever possible. Existing terms are
not available for every element of individualisation dis-
cussed in this review, thus new terms will be needed.
Patients often state that they want to be involved in
the long-term management of their drug treatments,
and some of them are already actively modifying their
drug treatments to suit their own requirements.7 In a
previous qualitative study, we found that healthcare pro-
viders are individualising treatments in their own way.3
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For example, doctors reported the use of graph paper
to help patients to monitor and track changes in their
symptoms, and to adjust medication accordingly.
However, strategies of this kind were not discussed in
any of the literature we reviewed. Indeed, the ‘patient’s
perspective’ was completely absent from much of the lit-
erature purporting to be about individualisation (eg,
pharmacogenetics). Some of the approaches presented
under the heading ‘long-term management of condi-
tions’ have the potential to support patients to modify
their medications over time; however, even among this
subgroup of papers, there is considerable variation in
the approaches discussed and the terms used to describe
them. Such approaches, while potentially promising,
tend to be modiﬁcations of research methods (such as
informal N-of-1 trials) which may lack clinical utility.
There is clearly a need for further research to be con-
ducted in this area, to develop strategies to support
patients and practitioners to safely modify treatments to
meet individual needs.
This is particularly true when considering multimor-
bidity and polypharmacy. In a recent King’s Fund
report, the challenges of treating patients with multimor-
bidity are discussed.44 The authors differentiate between
appropriate and problematic polypharmacy—the former
referring to the necessary treatment of complex patients
with multiple conditions, the latter to inappropriate
treatment. The main argument of the report is that
further research is necessary to make all polypharmacy
appropriate. However, because each patient is individual
—with individual conditions, responses, lifestyles, needs
and wants—it is difﬁcult to develop an evidence base for
treating multimorbidity that suits each individual. The
King’s Fund calls for the development of systems that
optimise medication use so that people gain maximum
beneﬁt with the least amount of harm and waste. This
would necessarily require the patient’s active involve-
ment. We suggest that MAT could be a useful term to
describe one such system. It refers to the ongoing
pharmacological management of conditions that incor-
porates patients’ speciﬁc needs, experiences and any
existing strategies for using their medications, and the
professionals’ clinical judgement. MAT would usually
involve patients monitoring their symptoms, with the
support of the professional, and making appropriate
product, dose or timing adjustments as necessary. As
there is evidence that patients7 and healthcare provi-
ders3 are already attempting to modify doses of treat-
ments to suit individual needs, we suggest that further
research looking at strategies to achieve MAT could be
beneﬁcial. This may involve strategies such as those men-
tioned in our previous study,3 and may also draw on the
literature presented in the present study. For example,
informal N-of-1 trials may also be a suitable strategy by
which MAT is achieved.
At present, there is a lack of consistency in the use of
the term individualisation in the literature. For many,
individualisation of treatment means pharmacogenetics.
Using the term MAT to refer to monitoring and modiﬁ-
cation of pharmacological treatment will avoid this con-
notation, thus improving the extent to which patients
and practitioners can discuss strategies to achieve MAT.
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